Goldman Sachs analyst Terence Flynn maintains Blueprint Medicines (NASDAQ:BPMC) with a Buy and raises the price target from $121 to $168.
Goldman Sachs Maintains Buy on Blueprint Medicines, Raises Price Target to $168
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.